Journal article
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations
Abstract
Non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which inhibits thrombin, and apixaban, betrixaban, edoxaban and rivaroxaban, which inhibit factor Xa. In large clinical trials comparing the NOACs with the vitamin K antagonist (VKA) warfarin, dabigatran, apixaban, rivaroxaban and edoxaban were at least as effective for stroke prevention in atrial fibrillation and for treatment of venous thromboembolism, but were …
Authors
De Caterina R; Ageno W; Agnelli G; Chan NC; Diener H-C; Hylek E; Raskob GE; Siegal DM; Verheugt FWA; Lip GYH
Journal
Thrombosis and Haemostasis, Vol. 119, No. 01, pp. 014–038
Publisher
Thieme
Publication Date
January 2019
DOI
10.1055/s-0038-1675816
ISSN
0340-6245
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Administration, OralAntibodies, Monoclonal, HumanizedAnticoagulantsArginineAtrial FibrillationBenzamidesBiomarkersBlood CoagulationClinical Trials as TopicDabigatranDrug Administration ScheduleFactor XaHeart DiseasesHumansPiperazinesPyrazolesPyridinesPyridonesRecombinant ProteinsRiskRivaroxabanStrokeThiazolesThrombinVenous ThromboembolismVitamin KWarfarin